<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00504816</url>
  </required_header>
  <id_info>
    <org_study_id>KG2107494</org_study_id>
    <nct_id>NCT00504816</nct_id>
  </id_info>
  <brief_title>A Study of the Effects of GSK189075 on PK Profiles of an Oral Contraceptive Pill When Given to Healthy Female Volunteers</brief_title>
  <official_title>An Open Label, Single-sequence, Repeat-dose Study to Investigate the Effects of GSK189075 on the Pharmacokinetics of an Oral Contraceptive Pill When Coadministered to Healthy Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to demonstrate a lack of effect of multiple doses of
      GSK189075 on the PK of an oral contraceptive pill in healthy female subjects. To estimate the
      effects of GSK189075 on hormonal levels and on birth control.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oral contraceptive pill (OC) drug levels</measure>
    <time_frame>over 24h starting on Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>blood hormone levels</measure>
    <time_frame>on Days 1, 11-14, &amp; 21 of Periods 1 (OC alone) &amp; 3 (OC plus GSK study drug). Period 2 is GSK drug study alone.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>all visits after study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECGs, Clinical laboratory tests</measure>
    <time_frame>screening &amp; follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vital signs</measure>
    <time_frame>screening;Day 13, Period 1 &amp; 3; Follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Brevicon</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Oral contraceptive used to determine pharmacokinetics when given with GSK189075 to look for interaction.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK189075</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Given in conjunction with Brevicon to see if GSK189075 interfered with Brevicon drug levels.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK189075</intervention_name>
    <description>Given with Brevicon to determine any effects of GSK189075 on Brevicon PK.</description>
    <arm_group_label>Brevicon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brevicon</intervention_name>
    <description>Given with GSK189075 to determine if GSK189075 exerts an effect on GSK189075 PK.</description>
    <arm_group_label>GSK189075</arm_group_label>
    <other_name>GSK189075</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy, non-smoking menstruating female age 18 to 45 years old, inclusive.

          -  able to take a specific oral contraceptive &amp; KG2107494.

          -  female unable to have any more children, still has ovaries and uterus, and has a
             negative pregnancy test.

          -  female who can have children and who has regular periods and are willing to use an
             oral contraceptive pill and/or have a sterile partner.

        Exclusion Criteria:

          -  pregnant or a nursing female.

          -  female subject able to have children of who is unwilling or unable to use an
             appropriate method of birth control at least 2 weeks prior to first dose of study drug
             until completion of the Follow-up visit.

          -  Have suffered with certain infection within 4 weeks prior to the first dose of study
             drug
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2007</study_first_submitted>
  <study_first_submitted_qc>July 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2007</study_first_posted>
  <last_update_submitted>May 31, 2012</last_update_submitted>
  <last_update_submitted_qc>May 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>healthy female,</keyword>
  <keyword>pharmacokinetics,</keyword>
  <keyword>pharmacodynamics</keyword>
  <keyword>drug interaction,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Norethindrone acetate, ethinyl estradiol, ferrous fumarate drug combination</mesh_term>
    <mesh_term>Norinyl</mesh_term>
    <mesh_term>Norethindrone</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Contraceptives, Oral, Combined</mesh_term>
    <mesh_term>Mestranol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

